Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Recruiting

ElranatamabElranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Sponsor:

Pfizer

Code:

NCT06057402

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elranatamab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-17. This information was provided to ClinicalTrials.gov by Pfizer on 2025-04-15.